A Study of SBO-154 for Advanced Solid Tumors
This study is testing a drug called SBO-154 in people with advanced solid tumors (cancers that start in organs like the breast, lung, or colon). You might be able to join if your cancer has not responded to standard treatments or you can't tolerate them. The main goals are to see how safe SBO-154 is, what side effects it might cause, and to find the highest dose that can be given safely. The study is looking for 177 participants and involves giving SBO-154 intravenously (into a vein) every three weeks. This is a Phase 1 study, meaning it's one of the first times SBO-154 is being tested in humans.
- Study design
- This is a Phase 1 interventional study with a planned enrollment of 177 participants. It has two parts, first to find a safe dose and then to evaluate safety in specific cancer types.
- What's involved
- You would need to attend scheduled visits, follow a treatment plan, and undergo laboratory testing and study procedures. You would receive SBO-154 intravenously every 3 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed for treatment-related serious adverse events and adverse events throughout the study, up to 30 days after your last dose of SBO-154.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
At a glance
Conditions
NCT07042100
Where you'd take part
This study runs at 16 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
All India Institute for Medical Sciences
Delhi, New Delhi, Indiastudy coordinator listed
Recruiting
Amrita Institute of Medical Sciences
Ernākulam, Kerala, Indiastudy coordinator listed
Not yet recruiting
Cancer Research South Australia
Adelaide, South Australia, Australiastudy coordinator listed
Recruiting
Honorhealth Research Institute
Scottsdale, Arizonastudy coordinator listed
Recruiting
Hope and Healing Clinical Research LLC
Hinsdale, Illinoisstudy coordinator listed
Recruiting
Kainos Super Speciality Hopsital
Rohtak, Haryana, Indiastudy coordinator listed
Not yet recruiting
MD Anderson Cancer Center
Houston, Texasstudy coordinator listed
Recruiting
Noble Hospital Pvt. Ltd.
Pune, Maharashtra, Indiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of dose-limiting toxicitiesTwenty-one days from the initiation of the first dose of SBO-154 (3 weeks)
Applicable to Part 1 only
- Incidence of treatment-related serious adverse eventsThroughout the study: from the start of study drug to 30 days post the last dose of study drug.
- Incidence of treatment-related adverse eventsThroughout the study: from the start of study drug to 30 days post the last dose of study drug.